Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study

Eur J Intern Med. 2019 Apr:62:9-16. doi: 10.1016/j.ejim.2018.12.010. Epub 2019 Jan 8.

¹ Hematology Unit, Azienda Ospedaliero-Universitaria, Modena, Italy. Electronic address: marco.marietta@unimore.it.
² Hematology Unit, Azienda Ospedaliero-Universitaria, Modena, Italy.
³ Cardiology Department, Maggiore Hospital, Bologna, Italy.
⁴ Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Parma, Italy.
⁵ Cardiovascular Medicine Unit, Azienda Ospedaliero-Universitaria, Modena, Italy.
⁶ Department of Angiology and Blood Coagulation, S. Orsola-Malpighi University Hospital, Bologna, Italy.
⁷ Haemostasis Centre, Fidenza-Vaio Hospital, Fidenza, Italy.
⁸ Cardiology Department, Bellaria Hospital, AUSL of Bologna, Italy.
⁹ Cardiology Division, Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
¹⁰ Servizio Strutture, Tecnologie e Sistemi Informativi, Regione Emilia-Romagna, Bologna, Italy.
¹¹ Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Italy.
¹² World Health Organization, Geneva, Switzerland.

No abstract available

Keywords: Anti-vitamin k; Apixaban; Atrial fibrillation; Dabigatran; Direct oral anticoagulants; Propensity score; Rivaroxaban.

Publication types